Abstract 159MO
Background
Standard dose of Abiraterone Acetate (AA) for metastatic CRPC is 1000mg/day in two divided doses to be taken on empty stomach. Food intake has shown alteration in pharmacokinetics of AA. Phase I studies have shown a 4.4 fold increase in drug absorption when taken with a high fat meal. Based on this hypothesis, studies have shown that low dose AA with a fatty meal is non inferior to standard dose. We did a prospective study of AA to confirm the same.
Methods
The primary objective of this study was to compare PSA response rate at 12 weeks with low dose (250mg) versus Standard dose (1000mg) Abiraterone Acetate. It was conducted from Dec 2019 to Dec 2020 and was a prospective randomised open-label study, where 70 consecutive patients with mCRPC were randomized in 1:1 ratio to receive low-dose AA ( 250 mg with a fatty meal) or Standard-dose AA (1000 mg in fasting state). Both groups received Prednisone at 5 mg twice daily. Recommended options for fatty meal included : a. Two teaspoons of Ghee b. Two teaspoons of Groundnut chutney c. Two teaspoons of clarified Butter.
Results
In the standard dose AA arm 32 out of 35 patients had bone metastasis while 3 patients had both bone and lymph nodal metastases. In low dose AA arm, 23 patients out of 35 had bone metastasis only while 12 patients had both bone and lymph nodal metastasis. Median baseline PSA level in the standard dose arm was 47 and in the low dose arm it was 65. At 12 weeks, in the standard AA arm, 2 patients out of 35 had PSA progression. The mean response to standard dose Abiraterone acetate was 68%. In the low dose AA arm, none of the patients had PSA progression. The mean response rate in the low dose arm was 82%. Fatigue (13 vs 12 patients in standard vs low dose arm respectively), Hypertension (12 vs 10 patients in standard vs low dose) hypokalaemia (11 patients in each arm) and fluid retention (9 vs 3 in standard vs low dose arm) were observed.
Conclusions
In metastatic CRPC, low dose AA taken with fatty meal is similar to standard dose AA in terms of PSA response and tolerance. In low resource countries like India, decreasing treatment costs will increase access to treatment, improve compliance and prevent interruption in treatment.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
158MO - Niraparib with abiraterone acetate and prednisone (NIRA+AAP) as first-line therapy in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) with homologous recombination repair (HRR+) gene alterations: Asian subgroup analysis of the MAGNITUDE study
Presenter: Marniza Binti Saad
Session: Mini Oral session: Genitourinary tumours
Resources:
Abstract
Slides
Webcast
160MO - Concomitant medication (conmed) interactions with novel hormonal agents (NHAs) in metastatic castration resistant prostate cancer (mCRPC)
Presenter: Ying Zhong
Session: Mini Oral session: Genitourinary tumours
Resources:
Abstract
Slides
Webcast
161MO - Efficacy and safety of relugolix in Asian men with advanced prostate cancer (APC): A subgroup analysis from the randomized, phase III HERO study versus leuprolide
Presenter: Dingwei Ye
Session: Mini Oral session: Genitourinary tumours
Resources:
Abstract
Slides
Webcast
Invited Discussant 158MO, 159MO, 160MO and 161MO
Presenter: Deborah Mukherji
Session: Mini Oral session: Genitourinary tumours
Resources:
Slides
Webcast
Q&A and discussion
Presenter: Deborah Mukherji
Session: Mini Oral session: Genitourinary tumours
Resources:
Slides
Webcast
136MO - Efficacy and safety of pembrolizumab (pembro) monotherapy in East Asian patients (pts) with urothelial carcinoma (UC) in KEYNOTE-045 or KEYNOTE-052
Presenter: Ravindran Kanesvaran
Session: Mini Oral session: Genitourinary tumours
Resources:
Abstract
Slides
Webcast
137MO - Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (UC): Longer-term follow-up from the Asian subgroup of the JAVELIN Bladder 100 trial
Presenter: Masatoshi Eto
Session: Mini Oral session: Genitourinary tumours
Resources:
Abstract
Slides
Webcast
138MO - A randomized study to compare outcomes of intravesical chemohyperthermia with mitomycin C vs intravesical BCG for intermediate and high risk non-muscle invasive bladder cancer (NMIBC)
Presenter: Karandeep Guleria
Session: Mini Oral session: Genitourinary tumours
Resources:
Abstract
Slides
Webcast
Invited Discussant 136MO, 137MO and 138MO
Presenter: Eiji Kikuchi
Session: Mini Oral session: Genitourinary tumours
Resources:
Slides
Webcast
Q&A and discussion
Presenter: Deborah Mukherji
Session: Mini Oral session: Genitourinary tumours
Resources:
Slides
Webcast